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Immunogenicity of Escherichia co/i 0 antigen
in upper urinary tract infection
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Immunogenicity of Escherichia coIl 0 antigen in upper urinary
tract infection. The role of immunogenicity of the infecting orga-
nism (Escherichia co/i) in the antibody response to 0 antigen in up-
per urinary tract infection was investigated. Heat-killed vaccines
were prepared from "immunogenic" organisms which had produced
upper urinary tract infection associated with high titers of hemag-
glutinating antibody to 0 antigen and "nonimmunogenic" orga-
nisms which had produced upper urinary tract infection without a
rise in antibody titer. "Immunogenic" 06 vaccine produced high ti-
ters of antibody in patients regarded as possibly "poor producers"
of antibody, but "nonimmunogenic" 011 vaccine was not associated
with a rise in titer in patients previously regarded as "good pro-
ducers". These vaccines were significantly different in immuno-
genicity (P <0.05). Five vaccines were tested in 50 rats. The differ-
ence in hemagglutinating titers toO antigen between 06 and 011 was
highly significant (P < 0.001). Immunogenicity of the infecting or-
ganism appears to be a significant factor in determining antibody re-
sponse to 0 antigen in upper urinary tract infection.
Immunogénicité de l'antigène 0 d'Escherichia coIl dans les infec-
dons du haut appareil urinaire. Le role de l'immunog6nicité de
l'organisme infectant (Escherichia co/i) dans Ia réponse immune a
l'antigène 0 au cours des infections du haut appareil urinaire a été
étudié. Des vaccins tués par Ia chaleur ont été préparés a partir
d'organismes "immunogéniques" qui ont été responsables
d'infection du haut appareil unnaire associées a des titres élevds
d'anticorps hémagglutinants contre l'antigène 0 et d'organismes
"non immunogéniques" qui ont produit une infeetion du haut appa-
reil sans augmentation du titre d'anticorps. Le vaccin "immu-
nogdnique" 06 produit des titres élevés d'anticorps chez des malades
considérés comme de faibles producteurs d'anticorps et Ic vaccin
"non immunogénique" 011 ne determine pas d'augmentation du
titre chez des malades antCrieurement considérds comme de "bons
producteurs". Ces vaccins diffrent significativement en "immu-
nogenicitd" (P < 0,05). Cinq vaccins ont été essayés chez 50 rats. La
difference dans les titres d'hémmaglutination vis a vis de l'antigene
0 est trCs significative entre 06 et 011 (P < 0,001). L'immuno-
gCnicitC de l'organisme infectant parait être un facteur important
dans Ia determination de Ia rCponse immune a l'antigene 0 au
cours des infections du haut appareil urinaire.
A rise in the serum antibody titer following urinary
infection with Escherichia co/i is well documented and
this rise was linked to the site of the infection in the
upper urinary tract by Brumffit and Percival [1]. The
finding that many infections localized to the upper
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tract bacteriologically did not produce a rise in he-
magglutinating antibody to the somatic 0 antigen of
the infecting strain of the E. co/i [2] was an unexpected
finding. In an attempt to find an explanation, three
possible factors have been considered: namely, a de-
fect in the patient's immune mechanisms; the possi-
bility that the site of infection in the upper tract could
be confined to the renal pelvis (pyelitis); and lastly
(thirdly) the immunogenicity of the strain of E. co/i.
The immunological capacity of the patients produc-
ing high and low antibodies to upper urinary tract in-
fections was tested by challenge with fiagellin [3] and
no significant difference in immunological response
was found.
The possibility that pyelitis may occur in human in-
fections was investigated using a technique of lavage
of the renal pelvis and determination of subsequent
bacterial excretion rates in urine collected through
ureteric catheters [4]. This provided little if any evi-
dence that urinary infections are limited to the renal
pelvis in man.
This paper reports an attempt to test the third possi-
bility, namely that the immunogenicity of different
strains of E. coli differs. The role of an antibody re-
sponse to 0 antigens in upper urinary tract infection
has been studied.
As the deliberate induction of upper urinary tract
infection in patients is ethically unacceptable, heat-
killed vaccines, the vaccine from the 011, were made
from three E. co/i organisms which had produced a
high 0 antibody response in patients and two E. co/i
organisms which had failed to do so, in spite of proven
upper urinary tract infection.
Methods
Nine women and one man, ranging in age from 22
to 62 yr, with frequent recurring urinary tract infec-
tions, were studied. All had a documented upper tract
infection determined bacteriologically by the bladder
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washout technique [5], five had failed to show a rise in
hemagglutinating antibodies to the infecting orga-
nisms and five had shown a significant rise to a titer of
I in 640 or more. (Although the importance of any
previous infection with the serotype used in the vac-
cine is realized, it is not possible to document the sero-
types of all previous infections with E. co/i going back
to infancy in any patient.) Serotyping had been avail-
able in the laboratory for three years prior to the study
and the previous urinary infections known to have oc-
curred in these patients over this period had been diag-
nosed by this laboratory, and serotyping of all E. co/i
infections was carried out over this period. No patient
had had a known infection with a coli of the same
serotype as the vaccine given.
Heat-killed vaccines were prepared by Dr. Gula-
sekharam, Commonwealth Serum Laboratories, Mel-
bourne, in strengths of 50 x 106 and 1000 x 106 orga-
nisms/mI. The organisms used were E. co/i 06, 075
and 05, which had produced infections associated with
a high hemagglutinating titer and were thus theo-
retically immunogenic, and E. co/i 011 and a non-
typable E. co/i, which had produced infection asso-
ciated with a very poor antibody response and were
thus possibly nonimmunogenic. All of these infections
had been localized to the kidney by the simple bladder
washout test [5]. 0 serotypes had been determined by
the method of Needell et a! [6] and hemagglutinating
antibodies by the technique of Neter et al [7].
The vaccines were made by the standard method of
the above Laboratories. E. co/i were grown up in veal
infusion agar in Roux bottles incubated at 37°C for 24
hr. The bacteria were harvested in saline solution and
heated to 60°C for 30 mm, and 0.5% phenol was add-
ed. Cell density was determined by opacity measure-
ment against standard opacity tubes and the vaccine
diluted to give the cell a density of 50 x 106 and
1000 x 106 organisms/mI. Vaccines were tested rou-
tinely for sterility and abnormal toxicity. The 06 and
Oil vaccines were administered subcutaneously to
patients in an initial dose of 0.1 ml of 50 x 106 orga-
nisms/mI (5 x 106 organisms). A total of nine in-
jections was given at three-day intervals, the total dose
being 2575 x 106 coli. The dose of E. co/i per injection
in millions was 5, 10, 20, 40, 100, 200, 400 and 800
with a final dose of 1000 million E. co/i. Blood for se-
rum antibodies was collected at monthly intervals (see
Table 1).
06 vaccine was given to five women who had per-
sistently low antibodies to the 0 antigen of their
homologous organism during an episode of symptom-
atic urinary infection prior to this study, theoretically
"poor producers" of antibody. 011 vaccine was given
to four women and one man in whom a significant an-
tibody rise had previously been demonstrated to an in-
fecting organism of another E. co/i serotype, theo-
retically "good producers" of antibody.
The vaccines were tested in laboratory rats as fol-
lows: Blood was taken for titer estimation before
treatment in all rats. Fifty adult rats (ten for each vac-
cine) were injected i.m. with 0.2 ml of 1000 x 106 or-
ganisms/mI f vaccine (200 x 106 organisms) on day
0 and were bled for a titer on day 5. On day 10 and day
20, a further 0.2 ml of vaccine was injected and blood
taken for titer estimation. A final blood sample was
taken on day 30. Antibody titers were determined by
the same method used in the human studies.
Results
Results of vaccination in patients with recurrent uri-
nary tract infection are shown in Table 1. Five patients
had had documented renal infection with persistently
low antibodies to their infecting organisms, "poor pro-
ducers." These patients received 06 vaccine. Four
showed a subsequent titer rise of at least two tube dilu-
tions and three had titers higher than 1:640. In the re-
maining patient, no such rise was demonstrated.
Table 1. Hemagglutinating antibody response to 06 vaccine in "poor producers" and to 01! vaccine in "good producers" of antibody toO
antigen expressed as reciprocal titer
Before
Patient treatment 1 month 2 months 3 months
1 80
Response to 06 vaccine in "poor producers"
640 1280 640
2 160 320 640 640
3 80 640 320 320
4 80 320 160 80
5 20 40
Response to 011 vaccine in "good producers"
20 20
6 40 80 80 80
7 160 80 40 40
8 40 80 80 80
9 40 80 80 40
10 20 160 80 20
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Five patients regarded as "good producers" had
had high titers of antibody to their homologous infect-
ing organism. These patients received 011 vaccine.
The maximum titer obtained was only 1:160.
Thus, following vaccination a titer above 1:640 oc-
curred in three of five patients receiving 06 vaccine, in
whom no such response to a urinary tract infection
with other coliform organisms had previously been
demonstrated. These patients were thus not "poor
producers" of antibody as they showed a response to
06 vaccine.
No titer above 1:160 occurred after 011 vaccination
in patients known to have produced antibody in high
titer to a previous urinary tract infection. These
patients were therefore not invariably "good pro-
ducers" of antibody. Using one-factor variance analy-
sis, peak titers after immunization with 06 vaccine
were significantly different from those against 011 us-
ing t test analysis of variance.
Results of vaccination in the rats, expressed as geo-
metric means of titer, are shown in Table 2 and Fig. 1.
Peak titers were usually recorded at 5 days and gener-
ally showed a slow decline over the 30-day interval. In
rats, of the three organisms associated with high anti-
body titers in human urinary infection, 06 was the
most and 011 the least immunogenic in the rat. The re-
sponse to 011 and the nontypable strain followed the
pattern seen in human infection, being associated with
lower antibody titers. Using one-factor variance anal-
ysis, peak titers following administration of 06 vaccine
were significantly higher than those produced by any
other vaccine (P < 0.01) and the difference between
06 and 011 was highly significant (P < 0.001).
Discussion
Escherichia coil is by far the commonest urinary
pathogen in man [8], and although there is consid-
erable geographical variation in 0-type distribution, a
limited number of serotypes are responsible for most
urinary infections.
Various factors have been suggested to explain the
prevalence of certain strains of E. co/i in patients with
urinary tract infection. Glynn, Brumfitt and Howard
[9] showed a greater proportion of E. coil strains rich
in K antigen in patients with urinary infection than in
controls and suggested that the excess of K-rich
strains was due to patients with renal infection. They
suggested that strains of E. co/i reached the bladder in
proportion to their frequency in fecal flora but that
strains rich in K antigen subsequently invaded the kid-
ney because of their relative resistance to phagocytosis
and killing by complement, and these would be more
likely to evoke an 0 antibody response.
The correlation of K-rich strains with titers of anti-
body to 0 antigen could reflect the immunogenicity of
these organisms, rather than their pathogenicity. Ma-
beck, Ørskov and Ørskov [10] found no correlation
between the individual 0, K or H antigens of the in-
fecting strain and renal involvement, although some
serotypes—02:K 1: H4, 04:K 12: H5 and 06: K2ac: H 1
were associated with a disproportionately high fre-
quency of symptomatic acute pyelonephritis. They
speculated that the antigen combination determining
serotype may be genetically linked to other character-
istics, which together constitute pathogenetic strains.
High titers of hemagglutinating antibody to the 0
antigen of the homologous infection E. co/i are found
more commonly in patients with upper than lower uri-
nary tract infection. Nonetheless, upper tract infection
frequently fails to evoke an antibody response [2].
In the present study, vaccination in both human
subjects and rats revealed significant differences in an-
tibody response to the 0 antigen of different strains of
E. coil studied. All these organisms had produced re-
nal infection in patients and were thus pathogenic. The
vaccines from the particular 06, 05 and 075 E. co/i
used in this study produced higher titers in rats than
011 and nontypable vaccines, as they had in the origi-
nal urinary infections in the patients from whom they
were isolated. Similarly, in patients, although the
Table 2. Range and geometric mean of reciprocal hemagglutinating antibody titers following E. co/i vaccination in adult rats
Vaccine
Before
treatment Day 5 Day 10 Day 20 Day 30
06 geometric mean
Range
05 geometric mean
Range
075 geometric mean
Range
NT geometric mean
Range
Oil geometric means
Range
4
0—8
9
0—16
5
0—16
4
0—8
5
0—16
830
64—4096
304
64—1024
36
8—256
16
8—32
7
0—32
194
64—1024
147
64—512
41
16—128
9
8—16
6
0—16
174
32—1024
84
16—512
46
16—128
9
8—16
11
8—32
194
128—512
60
8—256
42
16—128
II
8—16
15
0—64
NT = nontypable.
E. coli immunogenicity in urinary tract infection 319
numbers were small, this 06 vaccine produced signifi-
cantly higher titers than the 011 vaccine. No direct
comparison could be drawn between titers obtained in
differing species using different methods of immuniza-
tion, but the 06 vaccine was significantly more immu-
nogenic in both patients and rats than the 011 vaccine.
The same was true in the episodes of urinary tract in-
fection in the two patients from whom the 06 and 011
organism had been isolated. It is possible that vaccine
from other 06 and 011 strains (with differing K and H
antigens) could produce widely differing antibody re-
sponses from those obtained with the vaccines used in
this study. In our experience with human renal infec-
tion (C. M. O'Keefe, unpublished data), E. co/i 06 pro-
duced HA titers 1:640 in only four of 14 patients with
kidney infection due to this serotype. For 011, 05 and
075 the numbers were 0/1, 0/1 and 3/7, respectively.
Thus, the 0 antigen is not the only determinant of the
specific antibody response.
The wide range of titers seen in rats immunized with
a particular vaccine (Table 2) and the poor response of
patient 5 (Table 1) imply that, as would be expected,
the genetically controlled ability of the host to respond
to a specific immunogenic stimulus influences the im-
mune response in individual cases. However, it has
been shown that a group defect of humoral immune
capacity cannot explain the failure of many patients
with proven upper urinary tract infection to produce
hemagglutinating antibody in high titer to the homo-
logous infecting organism [3]. These results further
suggest that the poor response is not due simply to a
failure of production of antibody to polysaccharide 0
antigen. Patients with low titers to the homologous or-
ganism produced high titers following immunization
with 06 vaccine.
A failure of antibody response would be expected if
the upper tract infection diagnosed bacteriologically
on "ureteric urine" were limited to the renal pelvis.
When this was investigated [4] using a technique of
renal pelvic lavage followed by the measurement of
the bacterial excretion rate during a profound diuresis,
it was concluded that pyelitis, if it occurred, was rare.
As upper urinary tract infection in the human is al-
most always due to pyelonephritis, a failure of anti-
body response cannot be attributed to lack of paren-
chymal invasion.
This study indicates that immunogenicity of the in-
fecting organism appears to be a significant factor in
determining antibody response to 0 antigen in upper
urinary tract infection.
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